Bristol Myers beats quarterly revenue estimates on strong Opdivo sales

Core Insights - Bristol Myers Squibb exceeded Wall Street expectations for third-quarter revenue, driven by robust growth in its cancer immunotherapy and blood thinner Eliquis, which helped the company mitigate losses from other areas [1] Revenue Performance - The company reported strong revenue growth, particularly in its cancer immunotherapy segment and Eliquis, indicating a positive trend in its product portfolio [1] Market Impact - The performance of Bristol Myers Squibb reflects broader trends in the pharmaceutical industry, where innovative therapies are increasingly driving revenue despite challenges in other segments [1]